Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non‐ischaemic dilated cardiomyopathy
Authors:
- Jesús G. MirelisJMJesús G. Mirelis
- Luis Escobar‐LopezLELuis Escobar‐Lopez
- Juan Pablo OchoaJOJuan Pablo Ochoa
- Eduardo VillacortaEVEduardo Villacorta
- Guillem CasasGCGuillem Casas
- Nerea Mora‐AyestaránNMNerea Mora‐Ayestarán
- Roberto Barriales‐VillaRBRoberto Barriales‐Villa
- José M. García‐PinillaJGJosé M. García‐Pinilla
- Pablo E. García‐GranjaPGPablo E. García‐Granja
Open Access
- 22 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (7) , 1183-1196
Abstract
Aims: Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non‐ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM. Methods and results: Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end‐stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow‐up of 2.7 years (interquartile range 1.3–4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenic/likely pathogenic variants (positive genotype) and 151 (25.2%) had LGE. In survival analysis, positive LGE was associated with MVA and ESHF (both, p < 0.001) while positive genotype was associated with ESHF ( p = 0.034) but not with MVA ( p = 0.102). Classification of patients according to genotype (G+/G−) and LGE presence (L+/L−) revealed progressively increasing events across L−/G−, L−/G+, L+/G− and L+/G+ groups and resulted in optimized MVA and ESHF prediction ( p < 0.001 and p = 0.001, respectively). Hazard ratios for MVA and ESHF in patients with either L+ or G+ compared with those with L−/G− were 4.71 (95% confidence interval: 2.11–10.50, p < 0.001) and 7.92 (95% confidence interval: 1.86–33.78, p < 0.001), respectively. Conclusion: Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Scar assessment with CMR and genotyping should be considered to select patients for primary prevention implantable cardioverter‐defibrillator placement.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/0004)
- Instituto de Salud Carlos III (PI19/01283)
- Instituto de Salud Carlos III (PI20/0320)
This publication has 26 references indexed in Scilit:
- Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic DysfunctionCirculation, 2017
- Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated CardiomyopathyJACC: Heart Failure, 2017
- Defibrillator Implantation in Patients with Nonischemic Systolic Heart FailureNew England Journal of Medicine, 2016
- Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseasesEuropean Heart Journal, 2016
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Sudden Cardiac Death Risk Stratification in Patients With Nonischemic Dilated CardiomyopathyJACC, 2014
- Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated CardiomyopathyJAMA, 2013
- Prediction of Arrhythmic Events in Ischemic and Dilated Cardiomyopathy Patients Referred for Implantable Cardiac DefibrillatorCirculation: Cardiovascular Imaging, 2012
- Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophyThe American Journal of Cardiology, 2002
- The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial DysfunctionNew England Journal of Medicine, 2000